At the last check on Friday, Humacyte Inc.’s (NASDAQ:HUMA) stock was down -$0.03, moving down -0.99 percent to $3.51. The average number of shares traded per day over the past five days has been 1,378,725 shares. 3 times new highs have been achieved over the past 5 days, with a $0.24 gain in that time frame. In the last twenty days, the average volume was 629,751, while in the previous 50 days, it was 609,581.
Since last month, HUMA stock rose 16.06%. Shares of the company fell to $2.76 on 07/27/23, the lowest level in the past month. A 52-week high of $5.60 was reached on 05/08/23 after having rallying from a 52-week low of $1.96. Since the beginning of this year, HUMA’s stock price has risen by 66.11% or $1.40, and marked a new high 25 times. However, the stock has declined by -37.41% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
HUMA stock investors should be aware that Humacyte Inc. (HUMA) stock had its last reported insider trading activity 64 days ago on Jun 15. Dougan Brady W, the Director of the company, disposed of 500,000 shares for $3.12 on Jun 15. It resulted in a $1,558,750 divestment by the insider. Niklason Laura E sold 500,000 shares at an average price of $3.12 on Jun 15. The insider now owns 9,990,736 shares following the transaction. On Jun 15, 10% Owner Ayabudge LLC sold 500,000 shares at $3.12 apiece. The transaction was valued at $1,558,750.
Valuation Metrics
The stock’s beta is 0.99. Besides these, the trailing price-to-sales (P/S) ratio of 290.73, the price-to-book (PB) ratio of 4.44.
Financial Health
In the three months ended June 29, Humacyte Inc.’s quick ratio stood at 5.70, while its current ratio was 5.70, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.42, and the total debt-to-equity ratio was 0.61. Based on annual data, HUMA earned $86.14 million in gross profit and brought in $1.56 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -50.70%. Return on equity (ROE) for the past 12 months was -25.30%.
In Humacyte Inc.’s quarter-end financial report for June 29, it reported total debt of $36.25 million. HUMA’s revenue rose 2266.67% during the quarter, while net income inched up to $60000.0. While analysts expected Humacyte Inc. to report -$0.22 quarterly earnings, the actual figure was -$0.22 per share. During the quarter, the company generated -$24.63 million in EBITDA. The liabilities of Humacyte Inc. were 106.99 million at the end of its most recent quarter ended June 29. The value of shareholders’ equity is $103.44 million.
Technical Picture
This quick technical analysis looks at Humacyte Inc.’s (HUMA) price momentum. With a historical volatility rate of 165.71%, the RSI 9-day stood at 51.07% on 17 August.
With respect to its five-day moving average, the current Humacyte Inc. price is up by +7.34% percent or $0.24. At present, HUMA shares trade +17.39% above its 20-day simple moving average and +8.33% percent above its 100-day simple moving average. However, the stock is currently trading approximately -16.03% below its SMA50 and +1.89% above its SMA200.
Stochastic coefficient K was 45.89% and Stochastic coefficient D was 66.09%, while ATR was 0.39. Given the Stochastic reading of 32.04% for the 14-day period, the RSI (14) reading has been calculated as 52.68%. As of today, the MACD Oscillator reading stands at 0.12, while the 14-day reading stands at 0.31.
Analyst Ratings
Piper Sandler upgraded its rating on Humacyte Inc. (NASDAQ: HUMA) to a Neutral in a note to investors on August 14, 2023. The analysts firm previously had an Underweight rating on the stock.Humacyte Inc. (HUMA) has been rated Buy by analysts. According to 0 brokerage firms, HUMA is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Humacyte Inc. stock as buy, with 5 recommending it as overweight.
With a median target price of $5.50, the current consensus forecast for the stock is $3.50 – $16.00. Based on these forecasts, analysts predict Humacyte Inc. (HUMA) will achieve an average price target of $7.25.
